Aptuit hosted the free event which focused on Challenging Current Paradigms in Early Drug Development.
Stuart Needleman, President and Chief Operating Officer, Aptuit LLC, expressed appreciation to guests and presenters who participated in the second annual Science Day Event at The Aptuit Center for Drug Discovery & Development in Verona, Italy on May 16, 2012. "Once again, we were able to share a lively exchange of ideas in response to the insightful presentations delivered by distinguished members of the industry and academia," he said.
Aptuit hosted the free event which focused on "Challenging Current Paradigms in Early Drug Development."
"For the event, we engaged prominent and highly respected scientists, knowledgeable in early drug development, to deliver presentations during our full day’s agenda. Several of the speakers spoke of recent and innovative approaches that reduce the time, costs and attrition of drug development – the issues that are at the heart of our common concerns and interests," said Mark Hembarsky, Vice President and Site Director at Verona.
Last year Aptuit initiated the Aptuit Scientific Symposium at their Verona, Italy location. From this site, Aptuit offers a fully integrated offering of drug discovery and development services.
Referring to the 2011 Science Day, Mr. Needleman concluded, "Since the May 16, 2012 event repeated last year’s great success, we are looking forward to another Aptuit hosted symposium of its kind. Those who attended found it a valuable experience, and it provided the opportunity for our guests to have a firsthand encounter with Aptuit people with heads for science and hearts for service."
Details about the Science Day, including copies of the presentations, are available at the Aptuit Verona microsite: www.aptuit.com/Verona.
For press information, please contact Maria Garvey at Delfino Marketing either by phone at 914-747-1400 or by email: maria@delfino.com.
Drug Solutions Podcast: Novel Drug Delivery Approaches: Refining AAV Vector Deliveries
May 30th 2025In this podcast episode, we discuss novel approaches to drug delivery, specifically regarding adeno-associated virus (AAV) vectors, as viewed by two industry experts who recently exhibited at the annual ASGCT meeting.
Transformations in Drug Development for Cell and Gene Therapies
March 28th 2025As a recognized leader in immunophenotyping for clinical trials, Kevin Lang from PPD discusses how spectral flow cytometry is transforming drug development, particularly in cell and gene therapies like CAR-T. He also dives into his award-winning research, including his 2024 WRIB Poster Award-winning work, and his insights from presenting at AAPS PharmSci360.
Prokaryotics Licenses Gram-Negative Antibiotic Potentiator from Northern Antibiotics
June 26th 2025Prokaryotics will gain worldwide rights to develop, manufacture, and commercialize NAB741, a non-bioactive polymyxin designed to increase permeability of the outer membrane of Gram-negative bacteria.